NEW YORK, August 22, 2026, 6:24 a.m. EDT
- SELLAS gained 15.4% on Friday, increasing its equity value by approximately $416 million.
- No additional company filing was submitted with the move; the most recent SEC update was on August 11.
- SELLAS’ valuation of $3.12 billion is equivalent to 22.6 times its stated cash balance.
SELLAS Life Sciences Group, Inc. NASDAQ:SLS ended Friday at $15.46, marking a 15.4% increase. Based on its share count as of June 30, the gain represents an approximate $416 million boost in market capitalization. The figure is provisional, as the number of outstanding shares may have varied since the end of the quarter.
The surge occurred in the absence of a new company announcement. SELLAS’ most recent SEC filing is still its quarterly report from August 11. As a result, Friday’s market action reflects investor expectation rather than new clinical data.
The stock rose by 21.0% during the week and is up 54.4% across the past three weeks. It closed just 2.6% under its 52-week peak. Trading volume on Friday hit 15.2 million shares, roughly 1.7 times the three-month average.
| SELLAS checkpoint | Close | Weekly change | Volume |
|---|---|---|---|
| July 31 | $10.01 | — | 5.04 million |
| August 7 | $12.01 | up 20.0% | 5.12 million |
| August 14 | $12.78 | up 6.4% | 4.41 million |
| August 21 | $15.46 | up 21.0% | 15.20 million |
Positive sentiment around cancer vaccines boosted stocks in the sector. Moderna, Inc. NASDAQ:MRNA jumped 129.2% during the week, with Merck & Co., Inc. NYSE:MRK up 12.3%. SELLAS’ GPS vaccine employs a distinct platform and targets a separate indication, leaving the implications for its product unclear.
| Oncology name | August 14 close | August 21 close | Weekly change |
|---|---|---|---|
| Moderna NASDAQ:MRNA | $63.32 | $145.13 | up 129.2% |
| SELLAS NASDAQ:SLS | $12.78 | $15.46 | up 21.0% |
| Merck NYSE:MRK | $135.84 | $152.55 | up 12.3% |
| ImmunityBio NASDAQ:IBRX | $7.57 | $7.79 | up 2.9% |
The current valuation provides minimal justification based on cash holdings. SELLAS held $138.3 million in cash at the end of June, amounting to 4.4% of its $3.12 billion market capitalization on Friday. The bulk of the valuation is tied to the prospects of its pipeline.
| Valuation measure | Value | Investor reading |
|---|---|---|
| Friday market capitalization | $3.12 billion | Present market equity |
| Cash at June 30 | $138.3 million | 4.4% of capitalisation |
| Market value less cash | About $2.98 billion | Represents value of pipeline and other assets |
| Market capitalization / cash | 22.6 times | Relies heavily on trial performance |
The focus is on REGAL. The randomized Phase 3 study included 127 acute myeloid leukemia patients in second remission. The main outcome measure is overall survival. Final review will begin once the 80th death occurs, as the analysis is event-driven without a predetermined date.
Chief Executive Angelos Stergiou described the second quarter as “an important period of execution for SELLAS,” in the company’s August update. SELLAS has begun raising manufacturing and regulatory expenses in anticipation of a potential filing if REGAL proves successful. SELLAS results release
| Program | Stage | Current status | Next disclosed milestone |
|---|---|---|---|
| GPS / REGAL | Phase 3 | Ongoing, not accepting new participants | 80th event, followed by final review |
| SLS009 / tambiciclib | Phase 2 | 28 subjects enrolled as of August 10 | Initial results anticipated in Q4 2026 |
| SLS009 pancreatic program | Preclinical | Continuing development preparations | Data to be presented at a medical conference |
SLS009 offers an alternative approach. SELLAS previously observed a 33% overall response rate among 54 evaluable patients in a prior study involving relapsed or refractory AML. At the chosen twice-weekly dosing regimen, the response rate increased to 40%. However, these findings do not come from a randomized study.
The balance sheet eases short-term funding pressure but reflects previous dilution. SELLAS secured $82.9 million via warrant exercises in the first half. The number of shares outstanding increased by 31.9% between December 31 and June 30. Operating cash burn reached $16.4 million over six months.
| Capital measure | December 31, 2025 | June 30, 2026 | Change |
|---|---|---|---|
| Cash | $71.8 million | $138.3 million | +$66.5 million |
| Common shares | 153.1 million | 201.9 million | +31.9% |
| First-half operating cash use | — | $16.4 million | Almost unchanged from previous year |
| Warrant proceeds, first half | — | $82.9 million | Primary source of funding |
Wall Street holds a positive outlook on SELLAS, though analyst coverage is limited. The consensus is formed by just two analysts, whereas Moderna has 23 and Merck has 28. The average price target for SELLAS suggests a 110% potential increase, highlighting the disparity between strong optimism and sparse coverage.
| Company | Consensus | Analysts | Average target | Implied upside / downside |
|---|---|---|---|---|
| SELLAS | Buy | 2 | $32.50 | +110.2% |
| ImmunityBio | Strong Buy | 4 | $12.75 | +63.7% |
| Merck | Buy | 28 | $147.77 | -3.1% |
| Moderna | Hold | 23 | $91.39 | -37.0% |
No scheduled SELLAS catalyst is expected this week. Investors are monitoring to see if Friday’s trading volume continues and if the company reports REGAL’s 80th event. In the meantime, vaccine updates from competitors may influence sentiment, though they do not affect the likelihood of GPS success.
Risks: REGAL may fail to achieve its survival goal, or authorities might request additional information. SLS009 is still at an initial stage. Additional warrant redemptions or stock offerings could lead to dilution, and a broader sector pullback could erase gains ahead of any outcome specific to the company.
Related articles: NASDAQ:SLS
